Last reviewed · How we verify
S-1 plus CDDP
S-1 plus CDDP is a combination chemotherapy regimen that inhibits thymidylate synthase and causes DNA cross-linking to suppress cancer cell proliferation.
S-1 plus CDDP is a combination chemotherapy regimen that inhibits thymidylate synthase and causes DNA cross-linking to suppress cancer cell proliferation. Used for Gastric cancer, Gastroesophageal junction cancer, Esophageal cancer.
At a glance
| Generic name | S-1 plus CDDP |
|---|---|
| Sponsor | Taiho Pharmaceutical Co., Ltd. |
| Drug class | Combination chemotherapy (fluoropyrimidine + platinum agent) |
| Target | Thymidylate synthase (S-1); DNA (CDDP) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
S-1 is an oral fluoropyrimidine prodrug that inhibits thymidylate synthase, disrupting DNA synthesis. CDDP (cisplatin) is a platinum-based agent that forms DNA adducts and cross-links, preventing DNA replication and transcription. Together, they provide synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Gastric cancer
- Gastroesophageal junction cancer
- Esophageal cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Diarrhea
- Nephrotoxicity
- Peripheral neuropathy
- Stomatitis
Key clinical trials
- Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (PHASE3)
- Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) (PHASE3)
- Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma (PHASE2)
- Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) (PHASE3)
- A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma (PHASE2)
- A Benefit Population Atlas of nICT Versus nCT for LAGC
- Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma
- Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |